You are hereBlogs / admin's blog / Interleukins in Therapeutics

Interleukins in Therapeutics


By admin - Posted on 01 April 2014

PharmaTutor (April- 2014)
ISSN: 2347 - 7881

 

Received On: 13/02/2014; Accepted On: 21/02/2014; Published On: 01/04/2014

 

Author: Anjan Khadka
Department of Pharmacology,
AFMC, Pune, India
anjankhadka14@yahoo.com

 

ABSTRACT:
Interleukins are a subset of a larger group of cellular messenger molecules called cytokines, which are modulators of cellular behaviour. On the basis of their respective cytokine profiles, responses to chemokines, and interactions with other cells, these T-cell subsets can promote different types of inflammatory responses. During the development of allergic disease, effector TH2 cells produce IL-4, IL-5, IL-9, and IL-32.  IL-25, IL- 31, and IL-33 contributes to TH2 responses and inflammation. These cytokines have roles in production of allergen-specific IgE, eosinophilia, and mucus. ILs have role in therapeutics as well as diagnosis and prognosis as biomarker in various conditions. Therapeutic targeting of the IL considered to be rational treatment strategy and promising biologic therapy.

 

How to cite this article: A Khadka, Interleukins in Therapeutics, PharmaTutor, 2014, 2(4), 67-72


[ABSTRACT WITH CITATION]   [VIEW AS HTML]